Combination chemotherapy of advanced sarcomas in adults with “CYOMAD” (S7)
نویسندگان
چکیده
منابع مشابه
Combination chemotherapy with Methotrexate, Fluorouracil and Leucovorin in advanced Mycosis Fungoides
Background: Mycosis fungoides (MF) is a cutaneous T cell lymphoma. There are only palliative treatments in advanced stages with no cure. Most chemotherapy regimens have temporary effects with various side effects. Objective: The objective of this study was to assess the efficacy of a new chemotherapy regimens in advanced stages of MF. This regimens takes advantage of synergistic effect of metho...
متن کاملCombination Chemotherapy of Advanced
Seventy-three patients with advanced non-Hodgkin lymphoma were treated with bleomycin, Adriamycin, cyclophosphamide, vincristine (Oncovin) and prednisone (BACOP), administered intensively during a 7-wk induction course followed by intermittent cycles every 3 wk for a total of 28 wk. The objective response in 44 evaluable nonleukemic patients with diffuse histology was 86%, with 66% achieving a ...
متن کاملCombination Chemotherapy of Advanced Chronic
1 1 10 Blood. Vol. 60. No. 5 (November). 1982 The M-2 protocol (vincristine. cyclophosphamide. BCNU. melphalan. and prednisone) was administered monthly to 63 evaluable patients with advanced chronic lymphocytic leukemia. Complete remission (absence of all clinical and bone marrow evidence of leukemia) and partial response (>50% decrease in organ enlargement and reduction of WBC count to below ...
متن کاملCombination chemotherapy in advanced adrenocortical carcinoma.
BACKGROUND Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. METHODS We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on da...
متن کاملEfficacy and safety of endostar® combined with chemotherapy in patients with advanced soft tissue sarcomas.
BACKGROUND Soft tissue sarcomas (STS) are a heterogeneous group of tumors, and approximately 40-50% of patients with STS develop metastatic disease. The median overall survival of those patients was 12 months and their 5-year survival rate was 8%. Therefore, study on more effective treatment, especially the targeting therapies, is urgently needed. OBJECTIVE To evaluate the efficacy and safety...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 1982
ISSN: 0008-543X,1097-0142
DOI: 10.1002/1097-0142(19821101)50:9<1724::aid-cncr2820500912>3.0.co;2-1